Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 4Phase 2 2

Status

Terminated 2Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Solid Tumors 1Recurrence 1Ovarian Neoplasms 1Neoplasms 1Leukemia, Myeloid, Acute 1Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × birinapant × Clear all
NCT02756130 2025-05-13

Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)

Jonsson Comprehensive Cancer Center

Phase 1/2 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01486784 2021-06-24

A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia

Abramson Cancer Center at Penn Medicine

Phase 1/2 Terminated
27 enrolled 15 charts
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02587962 2021-01-14

Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

Medivir

Phase 1/2 Terminated
34 enrolled 27 charts
Other solid neoplasm

Solid Tumors

NCT01188499 2016-05-30

Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors

TetraLogic Pharmaceuticals

Phase 1/2 Completed
176 enrolled 13 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡